Study Reports Some Cases Of Delayed Rash After Moderna COVID-19 Vaccine Dose: Report
According to a New England Journal of Medicine report, some people experienced delayed skin rashes after receiving Moderna Inc’s (NASDAQ: MRNA) COVID-19 shot, writes Bloomberg.
Researchers reported details on 12 cases of reactions that appeared eight or more days after the first dose.
In some cases, the rashes were four inches wide or more and took around six days to resolve.
According to the study, most of the delayed reactions developed on the shoulder and upper arm near the injection site, while others appeared on the elbow, fingers, and palm.
In some cases, the tissue below the skin surface hardened and lost its smooth appearance in response to the inflammation.
The rashes were mostly treated with ice and antihistamines, although some patients needed steroid treatments.
About half also got skin reactions after the second dose, though less severe.
The delayed reactions to the Moderna vaccine are different from the immediate injection-site reactions common with both the Pfizer Inc (NYSE: PFE) and Moderna messenger RNA vaccines, said Kimberly Blumenthal, co-director of the clinical epidemiology program at Massachusetts General Hospital in Boston.
“This is a Moderna-specific reaction that pops up after the first week and can last a number of days.” “I have not been told about any from Pfizer,” Blumenthal said.
Price Action: MRNA shares are trading 1.54% lower at $129.2 in premarket trading on the last check Thursday.
See more from Benzinga
Pfizer's Lorbrena Wins Full FDA Approval As First Line Treatment Of ALK-Positive Lung Cancer
Emergent BioSolutions Capable Of Manufacturing 1B COVID-19 Vaccine Doses Annually, CEO Says
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
